Fig. 5From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancerKaplan–Meier estimates of risk factors for BCR in high-risk PCa treated with CHT, followed by RP with categorized based on the preoperative PSA level (a), pathological N stage (b), nuclear AR expression (c), and nuclear YAP1 expression (d)Back to article page